Aliviodol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aliviodol

Property Description
Active ingredient Meloxicam
Form Tablet, oral suspension, injection solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief of pain, inflammation, and fever
Origin Synthetic oxicam derivative

What Type of Medicine is Aliviodol?

Aliviodol is a medicinal preparation whose sole active ingredient is Meloxicam, a substance recognized as a cornerstone in the management of chronic musculoskeletal pain. It belongs to the established class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Meloxicam is chemically classified as a synthetic oxicam derivative, a compound within the enolic acid group of NSAIDs. The prescription-only status of this product underscores the requirement for professional oversight in its use.

The designation as an NSAID establishes its core therapeutic function and its capacity to address symptoms of inflammation and pain. Specifically, Meloxicam is categorized as a preferential cyclooxygenase-2 (COX-2) inhibitor, a key feature that distinguishes its mechanism within the NSAID group, supporting its clinical use for chronic inflammatory conditions in adults and pediatric patients.


Aliviodol’s Chemical Class and General Purpose

The medication's fundamental purpose is to mitigate symptoms like persistent pain, stiffness, and swelling. This is achieved through its recognized capacity to provide analgesic (pain relief), anti-inflammatory (swelling reduction), and inherent antipyretic (fever reduction) properties.

The general purpose of Aliviodol, therefore, centers on symptomatic management for inflammatory states, such as those associated with osteoarthritis and rheumatoid arthritis, helping to improve the functional status of the patient. The drug maintains a recognized utility in basic pain management.


Available Forms of Aliviodol

As a single-component product, Aliviodol is supplied in multiple dosage forms to accommodate varied administration needs. These preparations typically include the standard tablet and an oral suspension for oral administration.

The product's flexibility extends to a sterile solution for injection, allowing for parenteral administration when oral dosing is unsuitable or a rapid onset is required. The final composition of each form contains the active substance Meloxicam combined with necessary, inert pharmaceutical excipients required to create a stable and administrable product suitable for the intended route of administration.

Regulatory References

  1. MedlinePlus Drug Information (Meloxicam)

What side effects are possible with Aliviodol?

Possible Side Effects and Safety Information

The safety profile for Aliviodol is established through regulatory review and is categorized by frequency and system-organ class.

Regulatory documents emphasize two critical safety warnings:

  • Serious Cardiovascular Thrombotic Events: Official labeling includes a Boxed Warning regarding the increased risk of serious, potentially fatal, cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke. This risk may occur early in treatment and may increase with the duration of use.
  • Serious Gastrointestinal Adverse Events: A second Boxed Warning covers the risk of serious gastrointestinal events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal and can occur without warning.

Adverse Reactions by Frequency

Adverse reactions documented in official sources are classified according to frequency:

Classification Examples of Documented Reactions
Very Common (≥ 1/10) Dyspepsia, abdominal pain
Common (≥ 1/100 to < 1/10) Nausea, vomiting, headache, dizziness, rash
Rare (< 1/1,000) Anaphylactic reactions, blood dyscrasias

Safety Restrictions and Considerations

Official documents define certain conditions where use is limited or restricted:

  • Contraindications: Aliviodol is contraindicated in patients with known hypersensitivity to the drug or other NSAIDs, severe uncontrolled heart failure, active gastrointestinal bleeding or ulceration, and in the setting of coronary artery bypass graft (CABG) surgery.
  • Pregnancy: Use is contraindicated during the third trimester of pregnancy due to risks to the fetus, including premature closure of the ductus arteriosus.
  • Elderly Patients: There is a documented increased risk for serious gastrointestinal adverse events in the elderly population.

Overdose and Emergency Response

Overdose and when to seek help

Mandated Emergency Actions

Urgent medical care is required upon the suspicion of an Aliviodol overdose. Regulatory documents state that immediate medical attention must be sought in all cases of suspected overdose. Emergency services (such as 911) must be contacted immediately if the patient collapses, exhibits seizure activity, experiences difficulty breathing, or becomes unresponsive. Guidance also requires contacting a Poison Control Center for immediate assistance and professional direction.

Documented Overdose Manifestations

Overdose may present with common clinical signs focused on the gastrointestinal and nervous systems. These documented manifestations include Nausea, Vomiting, and Epigastric pain, along with systemic effects such as Lethargy and Drowsiness. Severe presentations may involve gastrointestinal bleeding (e.g., bloody or black, tarry stools).

Potential Severe Outcomes

Official labeling warns that severe overdose may lead to life-threatening complications. Documented critical outcomes include Acute renal failure, Respiratory depression, Coma, and Cardiovascular collapse.

Overdose Management Procedures

There is no specific antidote known for Meloxicam toxicity. Management, as defined by regulatory authorities, relies entirely on symptomatic and supportive care. Procedures such as gastric lavage and the administration of activated charcoal may be used in an attempt to limit systemic drug absorption. Techniques such as hemodialysis are noted as typically ineffective due to the drug’s high protein-binding characteristics.

Therapeutic Uses of Aliviodol

What Aliviodol Treats: Main Uses and Benefits

Aliviodol is commonly used for the sustained symptomatic management of chronic inflammatory joint conditions in adults and pediatric patients. These conditions include Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Idiopathic Arthritis (JIA).

The medication plays a role in managing symptom clusters that may become intense or disruptive, contributing to the easing of pain, swelling, and stiffness. It is relevant for managing symptoms that interfere with daily comfort, such as moderate-to-severe discomfort and limited joint mobility, and is applied in situations where patients experience recurrent discomfort.

The drug is also commonly used to help with systemic symptoms, including managing fever associated with inflammatory processes. Furthermore, it is relevant when supportive symptom management is appropriate in general clinical settings, such as managing post-operative pain and inflammation following certain medical procedures. This applied symptomatic support helps ease the overall symptom burden during phases when symptoms become more noticeable.

“The primary goal of using this medication is offering symptomatic support to help patients better cope with the persistent, daily discomfort of chronic inflammatory diseases.”

Quick Fact: Relief for Joint Pain and Stiffness
Symptom Type: Inflammatory pain, swelling, and chronic stiffness.
Conditions: OA, RA, and JIA in specific pediatric populations.
Benefit: Assists with managing symptoms that interfere with routine activities.

Regulatory References

  1. NIH DailyMed overview for Meloxicam

Eligibility and Restrictions for Use

The eligibility for using Aliviodol (Meloxicam) is strictly defined by regulatory authorities based on age, existing medical conditions, and physiological status.

Populations for whom use is Contraindicated

Meloxicam must not be used by the following populations, as stated in official labeling:

  • Patients with a known hypersensitivity to Meloxicam or who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
  • In the setting of Coronary Artery Bypass Graft (CABG) surgery (for peri-operative pain).
  • Those with active or recurrent gastrointestinal bleeding or peptic ulceration or a history of related perforation.
  • Individuals with severe uncontrolled heart failure, severe uncompensated hepatic impairment, or severe non-dialyzed renal impairment.

Age and Physiological Limitations

Category Eligibility Rule (as documented in label)
Pediatric Use Use is contraindicated in children under 2 years of age. Approved for children aged 2 years and older for Juvenile Idiopathic Arthritis (JIA) only.
Geriatric Use Use is permitted, but older adults have a higher risk for serious adverse reactions, requiring special caution.
Pregnancy Contraindicated in the third trimester (from about 30 weeks gestation). Use between 20 and 30 weeks should be limited due to risk of fetal renal dysfunction.
Lactation Use is not recommended while breastfeeding, as the medicine may be excreted in human milk.

Eligibility is also restricted for patients with conditions such as uncontrolled hypertension or a history of certain cardiovascular events.

What should I know about interactions with other medicines?

The interaction profile of Aliviodol is officially classified by regulatory authorities based on pharmacodynamic and pharmacokinetic mechanisms that affect the exposure and safety risk of co-administered substances.

Documented Pharmacodynamic Interactions

Co-administration with other medications that affect hemostasis or the gastrointestinal lining increases documented risk and is often prohibited or discouraged:

  • Other NSAIDs, including aspirin (at anti-inflammatory doses): Concomitant use is formally contraindicated or not recommended due to an additive risk of gastrointestinal adverse events, including bleeding and ulceration.
  • Oral Anticoagulants (e.g., Warfarin), Anti-platelet Agents, and SSRIs/SNRIs: Combination increases the official risk of hemorrhage.
  • Diuretics and Antihypertensives (e.g., ACE inhibitors, ARBs): Combination may diminish the blood pressure-lowering effect and carries a risk of renal function deterioration. This risk is heightened in elderly or volume-depleted patients.

Exposure-Altering Combinations

Meloxicam alters the systemic exposure of certain co-administered drugs due to reduced renal clearance, a documented pharmacokinetic interaction:

  • Lithium and Digoxin: Co-administration increases the plasma concentration of both substances.
  • Methotrexate: Use with Aliviodol may increase Methotrexate concentrations and prolong its residence, enhancing the risk of toxicity, which is a documented concern.

Formal Regulatory Restrictions

  • Aliviodol is explicitly contraindicated for the treatment of pain in the setting of coronary artery bypass graft (CABG) surgery.
  • The oral suspension formulation is specifically contraindicated for co-administration with Sodium Polystyrene Sulfonate due to a documented risk associated with an excipient.

Mechanism of Action

Targeted Action on Key Receptor Systems

Aliviodol initiates its activity by engaging specific, high-affinity receptor sites within defined regulatory systems. The mechanism is defined by the selective nature of this interaction, which contributes to a focused adjustment of signaling balance.

Dampening Signal Transduction Cascades

Following the initial receptor binding, Aliviodol operates to attenuate downstream signaling events within molecular cascades. This mechanistic action limits the amplification of cellular messages, modifying early molecular steps which results in the suppression of subsequent mediator activity.

Modulating Central and Peripheral System Balance

The mechanism of action supports the regulation of pathway activity across both central and peripheral physiological contexts. By influencing signaling dynamics in defined systems regardless of anatomical location, this action defines the characteristics of the resulting physiological response.

Dosage and Administration Information

Official Administration Principles

Aliviodol (Meloxicam) is administered through two primary routes: oral (using tablets or a liquid suspension) and intravenous (IV) injection. The oral route is generally designated for chronic management, while the IV route is utilized for managing moderate-to-severe pain.

The overarching principle for use dictates that treatment must employ the lowest effective dosage for the shortest duration necessary to achieve the therapeutic goal. Dosing frequency for all approved regimens is standardized to once daily.

Standardized Daily Dosing

Administration Route Indication Context Standard Dose Range Maximum Daily Dose
Oral Chronic conditions (OA, RA) 7.5 mg to 15 mg 15 mg
Intravenous Acute pain management 30 mg (fixed dose) 30 mg

Key Procedural Instructions

Oral dosage forms may be taken with or without food. However, official instructions require specific handling for certain forms and populations. The oral suspension must be gently shaken prior to use.

Furthermore, a dose adjustment applies to specific patient groups: the maximum daily dose is restricted to 7.5 mg for patients undergoing hemodialysis. For intravenous use, the 30 mg dose must be administered as a bolus injection over at least 15 seconds, and patients must be confirmed as well-hydrated before receiving the injection. Standard pharmacological guidelines indicate that different oral forms are not interchangeable.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Focus and Biological Pathways

The research reviewed for this summary focused on two key biological pathways. Studies have explored the relationship between use of the compound and reported outcomes in individuals with mild to moderate conditions. Some studies have examined the timeline for the observation of effects. Research also looked at whether the compound was linked to a lasting change in inflammatory markers.


Studies on Chronic Pain

A clinical trial examined the relationship between the compound and measured endpoints, such as pain scores, over a 12-week period. Ongoing research is examining the compound in further studies.


Studies on Adverse Events and Tolerability

Available data from studies have evaluated the occurrence of adverse events during long-term use. The most commonly reported events included gastrointestinal distress and headaches.


Research Evaluating Co-Administration with Agent X

One study assessed the relationship between co-administration and measured endpoints. Further research is needed to understand the circumstances under which co-administration is explored.

Key Studies & References

  1. NICE Clinical Guideline: Management of Chronic Primary Pain in Adults

Frequently Asked Questions (FAQ)

Common questions about Aliviodol (FAQ)


Q: Is Aliviodol a narcotic or a controlled substance?

According to official drug information, Aliviodol (Meloxicam) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

It is not designated as a narcotic, nor is it listed as a controlled substance under regulatory acts like the US Controlled Substances Act.


Q: How quickly should I expect Aliviodol to start working?

Regulatory information describes the time to maximum concentration (Tmax) in the bloodstream is approximately 5 to 6 hours after an oral dose.

However, the time required to observe the full therapeutic effect, particularly for chronic conditions, may take several days or weeks of treatment.


Q: Does Aliviodol cause drowsiness or make you tired?

Official drug labeling lists dizziness as a Common adverse reaction.

Somnolence, which refers to drowsiness, is also noted as an Uncommon adverse reaction.


Q: What foods or drinks should be avoided while using Aliviodol?

Official instructions for the oral forms of Aliviodol state they can be taken with or without food.

Regulatory documents do not list any general food restrictions that must be avoided while using this medication.


Q: Is there a maximum time someone can take Aliviodol for?

The official regulatory guidance emphasizes using the lowest effective dosage for the shortest duration necessary to achieve the therapeutic objective.

This principle is established based on the documented risk of serious cardiovascular and gastrointestinal adverse events associated with the medicine.


Q: Is it safe to drive after taking Aliviodol?

Official product labeling states that caution is necessary when driving or operating machinery.

This is because documented adverse reactions such as dizziness, somnolence (drowsiness), or visual disturbances may affect a person's ability to drive safely.


Q: Will Aliviodol interfere with anesthesia if I need surgery?

According to regulatory documents, Aliviodol is explicitly contraindicated for the treatment of peri-operative pain following coronary artery bypass graft (CABG) surgery.

Guidance concerning other surgical procedures or anesthesia requires consultation with a healthcare professional.


Q: Does the time of day matter when taking Aliviodol?

Regulatory documents standardize the dosage frequency to once daily.

However, the official instructions do not define a specific optimal time of day (such as morning versus evening) for administration.


Q: What is the official approval status of Aliviodol in the US/EU?

Aliviodol (Meloxicam) is an FDA-approved and EMA-authorized prescription drug.

Official documents from these regulatory bodies define its approved uses, indications, and established safety profile based on regulatory review.


Q: What should a person do before starting Aliviodol?

Regulatory guidance indicates that a medical assessment is necessary before starting this medication.

This involves reviewing factors such as cardiovascular risk, any history of gastrointestinal problems, and checking both renal (kidney) and hepatic (liver) function.


Q: Can Aliviodol affect your mood or mental state?

Official drug labeling documents psychiatric disorders as an Uncommon adverse reaction.

These effects have been noted to include mood alteration, nightmare, and confusion.


Q: What happens if I forget to take Aliviodol?

Instructions for missed doses, found in regulatory patient information, generally advise taking the dose as soon as it is remembered.

However, if it is almost time for the next scheduled dose, the missed dose is generally skipped to avoid potential overexposure.


Q: Is there any known interaction between Aliviodol and alcohol?

Regulatory documents generally caution that the use of NSAIDs like Aliviodol at the same time as consuming alcohol may increase the risk of gastrointestinal bleeding or related adverse events.


Q: Can Aliviodol be taken with contraceptive pills?

While official interaction tables may not specifically list all oral contraceptives, regulatory guidance generally advises caution with medicines that affect kidney function.

Some NSAIDs are noted in medical literature as potentially reducing the efficacy of certain birth control methods.


Q: Is Aliviodol known to cause weight gain?

Official regulatory labeling lists peripheral edema (swelling) and fluid retention as documented side effects.

These effects, which are related to fluid retention, may be observed as changes in body weight.


Q: What is the shelf life of Aliviodol?

The official shelf life and expiration dates for the medicine are defined by the manufacturer and established in the product's regulatory documentation.

This information is typically printed on the product's packaging and container.


Q: Is Aliviodol gluten-free or suitable for specific diets?

The official labeling documents all excipients, which are the inactive ingredients used in the formulation.

This information is available in the regulatory paperwork and allows for verification regarding the presence or absence of specific substances like gluten.


Q: Can Aliviodol be split or crushed?

The product label specifies whether tablets are scored or may advise against altering the dosage form, such as splitting or crushing.

Consultation of the official patient information is necessary, as altering a tablet can affect how the medicine works.


Q: Does Aliviodol make you sensitive to the sun?

Photosensitivity reactions, which involve an increased sensitivity to sunlight, are listed as a documented adverse reaction in the official product labeling.

Official information indicates that protection from the sun is typically necessary when photosensitivity is a documented side effect.


Q: Are generic versions of Aliviodol available?

Since Aliviodol’s active ingredient is Meloxicam, generic equivalents are commonly available.

Government resources, such as the FDA Orange Book, list approved drug products and their generic status.


Q: How long does Aliviodol stay in your system?

Regulatory documents define the elimination half-life (T1/2) of the active ingredient, Meloxicam, as approximately 15 to 20 hours.

This is the time it takes for half of the medicine to be cleared from the body.


Q: Is there a risk of dependency with Aliviodol?

As a Nonsteroidal Anti-inflammatory Drug (NSAID), Aliviodol is not associated with the risk of physical dependency or abuse.

This is a classification distinction from opioid medications.

How should Aliviodol be stored and disposed of?

Storage and Disposal of Aliviodol (Meloxicam)

The official labeling for Aliviodol, an NSAID, defines specific conditions necessary to preserve the product's integrity.

Required Storage Conditions

The medication must be stored at Controlled Room Temperature, generally 20 C to 25 C (68 F to 77 F). It is essential to keep the medicine from freezing and to protect it from excess heat, moisture, and direct light. Always store Aliviodol in its original container, ensuring the container is tightly closed to maintain stability. The product must always be stored out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Aliviodol must not be thrown into household trash or flushed down the toilet. For proper disposal, individuals should contact a healthcare professional or pharmacist to utilize an authorized medicine take-back program, adhering to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aliviodol found in:

A-Z Index: